Effects of colistin on biofilm matrices of Escherichia coli and Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 49, Issue 4, 2017, Pages 472-479

  Klinger Strobel, Mareike ^a   Stein, Claudia ^a,b   Forstner, Christina ^a,c   Makarewicz, Oliwia ^a,b   Pletz, Mathias W ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b InfectoGnostics Research Campus ^*  (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antibiotic resistance; Biofilm quantification; Combined antibiotic treatment; MRSA; Nosocomial infection; Polymyxin

Indexed keywords

COLISTIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BIOFILM; COLONY FORMING UNIT; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG EFFICACY; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BIOFILM ERADICATION CONCENTRATION; NONHUMAN; PLANKTON; BACTERIAL COUNT; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; DRUG EFFECTS; ESCHERICHIA COLI INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; STAINING; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BIOFILMS; COLISTIN; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; MICROSCOPY, CONFOCAL; STAINING AND LABELING; STAPHYLOCOCCAL INFECTIONS;

EID: 85014671202     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.005     Document Type: Article

References (33)

1. [1] Falagas, M.E., Kasiakou, S.K., Saravolatz, L.D., Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005), 1333–1341.
2. [2] Mendes, C.A.C., Burdmann, E.A., Polymyxins: review with emphasis on nephrotoxicity. Rev Assoc Med Bras (1992) 55 (2009), 752–759 in Portuguese.
3. [3] Chen, C.C., Feingold, D.S., Locus of divalent cation inhibition of the bactericidal action of polymyxin B. Antimicrob Agents Chemother 2 (1972), 331–335.
4. [4] Falagas, M.E., Kasiakou, S.K., Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care, 10, 2006, R27.
5. [5] Poulikakos, P., Tansarli, G., Falagas, M., Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33 (2014), 1675–1685.
6. [6] Zavascki, A.P., Bulitta, J.B., Landersdorfer, C.B., Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11 (2013), 1333–1353.
7. [7] Li, J., Nation, R.L., Turnidge, J.D., Milne, R.W., Coulthard, K., Rayner, C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6 (2006), 589–601.
8. [8] Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E.M., Tumietto, F., Marchese, A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55 (2012), 943–950.
9. [9] Langan, K.M., Kotsimbos, T., Peleg, A.Y., Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Curr Opin Infect Dis 28 (2015), 547–556.
10. [10] Langton Hewer, S.C., Smyth, A.R., Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev(11), 2014 CD004197.
11. [11] Tumbarello, M., De Pascale, G., Trecarichi, E.M., De Martino, S., Bello, G., Maviglia, R., et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible Gram-negative bacteria. Chest 144 (2013), 1768–1775.
12. [12] Klinger-Strobel, M., Suesse, H., Fischer, D., Pletz, M.W., Makarewicz, O., A novel computerized cell count algorithm for biofilm analysis. PLoS ONE, 11, 2016 e0154937.
13. [13] Sobke, A., Klinger, M., Hermann, B., Sachse, S., Nietzsche, S., Makarewicz, O., et al. The urinary antibiotic 5-nitro-8-hydroxyquinoline (nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother 56 (2012), 6021–6025.
14. [14] Klinger-Strobel, M., Lautenschläger, C., Fischer, D., Mainz, J.G., Bruns, T., Tuchscherr, L., et al. Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis—where do we stand?. Expert Opin Drug Deliv 12 (2015), 1351–1374.
15. [15] Moskowitz, S.M., Foster, J.M., Emerson, J., Burns, J.L., Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42 (2004), 1915–1922.
16. [16] Römling, U., Balsalobre, C., Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 272 (2012), 541–561.
17. [17] Bereket, W., Hemalatha, K., Getenet, B., Wondwossen, T., Solomon, A., Zeynudin, A., et al. Update on bacterial nosocomial infections. Eur Rev Med Pharmacol Sci 16 (2012), 1039–1044.
18. [18] Edmond, M.B., Masroor, N., Stevens, M.P., Ober, J., Bearman, G., The impact of discontinuing contact precautions for VRE and MRSA on device-associated infections. Infect Control Hosp Epidemiol 36 (2015), 978–980.
19. [19] Proctor, R.A., Von Eiff, C., Kahl, B.C., Becker, K., McNamara, P., Herrmann, M., et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4 (2006), 295–305.
20. [20] Corvec, S., Furustrand Tafin, U., Betrisey, B., Borens, O., Trampuz, A., Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 57 (2013), 1421–1427.
21. [21] Young, K.D., Bacterial morphology: why have different shapes?. Curr Opin Microbiol 10 (2007), 596–600.
22. [22] Grégoire, N., Mimoz, O., Mégarbane, B., Comets, E., Chatelier, D., Lasocki, S., et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 58 (2014), 7324–7330.
23. [23] Luque, S., Li, J., Escaño, C., Sorli, L., Campillo, N., Esteve, E., et al. Urinary concentrations of colistimethate sodium (CMS) and formed colistin in patients with MDR Gram-negative bacterial (MDR-GNB) infections after intravenous administration. 25th European congress of clinical microbiology and infectious diseases (ESCCMID 2015); 25–28 April 2015; Copenhagen, Denmark. Basel, Switzerland: ESCMID, 2015 [EV0073].
24. [24] Grossman, T.H., O'Brien, W., Kerstein, K.O., Sutcliffe, J.A., Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother 59 (2015), 2446–2449.
25. [25] Sala, C., Morar, A., Colibar, O., Morvay, A.A., Antibiotic resistance of Gram negative bacteria isolated from meat surface biofilm. Rom Biotech Lett 17 (2002), 7483–7492.
26. [26] Klinger-Strobel, M., Gläser, S., Makarewicz, O., Wyrwa, R., Weisser, J., Pletz, M.W., et al. Bactericidal effect of a photoresponsive carbon monoxide-releasing nonwoven against Staphylococcus aureus biofilms. Antimicrob Agents Chemother 60 (2016), 4037–4046.
27. [27] Baron, S., Hadjadj, L., Rolain, J.M., Olaitan, A.O., Molecular mechanisms of polymyxin resistance: knowns and unknowns. Int J Antimicrob Agents 48 (2016), 583–591.
28. [28] Betts, J.W., Phee, L.M., Hornsey, M., Woodford, N., Wareham, D.W., In vitro and in vivo activities of tigecycline–colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 58 (2014), 3541–3546.
29. [29] Stein, C., Makarewicz, O., Bohnert, J.A., Pfeifer, Y., Kesselmeier, M., Hagel, S., et al. Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates. PLoS ONE, 10, 2015 e0126479.
30. [30] Teuber, M., Bader, J., Action of polymyxin B on bacterial membranes. Binding capacities for polymyxin B of inner and outer membranes isolated from Salmonella typhimurium G30. Arch Microbiol 109 (1976), 51–58.
31. [31] Evans, M.E., Feola, D.J., Rapp, R.P., Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 33 (1999), 960–967.
32. [32] Garcia, L.G., Lemaire, S., Kahl, B.C., Becker, K., Proctor, R.A., Denis, O., et al. Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J Antimicrob Chemother 68 (2013), 1455–1464.
33. [33] Tuchscherr, L., Medina, E., Hussain, M., Volker, W., Heitmann, V., Niemann, S., et al. Staphylococcus aureus phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. EMBO Mol Med 3 (2011), 129–141.